Navaneethan Udayakumar, Lourdusamy Dennisdhilak, Gutierrez Norma G, Zhu Xiang, Vargo John J, Parsi Mansour A
Center for Interventional Endoscopy, Orlando, Florida, United States.
Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, United States.
Endosc Int Open. 2017 Aug;5(8):E710-E717. doi: 10.1055/s-0043-102398. Epub 2017 Aug 7.
Endoscopic retrograde cholangiopancreatography (ERCP) is often performed in patients with primary sclerosing cholangitis (PSC). Our aim was to validate a treatment approach with the objective of decreasing ERCP related adverse events (AEs).
All patients who had undergone ERCP for PSC during the period from 2002 - 2012 were identified (group I). This group had traditional ERCP (no bile aspiration prior to contrast injection with balloon dilation and stent placement for treatment of dominant strictures). To decrease ERCP-related AEs, we changed the ERCP approach in which bile aspiration was performed prior to contrast injection and balloon dilation alone was performed for treatment of dominant strictures. This was tested prospectively in all patients undergoing ERCP for PSC from 2012 - 2014 (group II).
The risk of overall AEs and cholangitis was relatively less in group II compared with group I [(2.1 % vs. 10.3 %; = .38) and (0 % vs. 4.4 %; = .68)]. On bivariate analysis, change in ERCP approach was associated with decreased risk of post-procedure cholangitis (0 % vs. 10.2 %, .03) and overall AE (0 % vs. 18.6 %, .03). There were no AEs in 22/46 patients in group II who had bile aspiration with balloon dilation. On multivariate analysis, only biliary stent placement was associated with increased risk of AEs (OR 4.10 (1.32 - 12.71); = .02) and cholangitis (OR 5.43, 1.38 - 21.38; = .02) respectively.
Biliary aspiration and avoidance of stenting approach after dilation of strictures during ERCP in PSC patients appears to be associated with decreased risk of cholangitis and overall AEs. Future prospective randomized controlled trials are needed to validate our observation.
内镜逆行胰胆管造影术(ERCP)常用于原发性硬化性胆管炎(PSC)患者。我们的目的是验证一种治疗方法,以减少与ERCP相关的不良事件(AE)。
确定了2002年至2012年期间因PSC接受ERCP的所有患者(第一组)。该组采用传统的ERCP(在注射造影剂前不进行胆汁抽吸,采用球囊扩张和支架置入治疗主要狭窄)。为了减少与ERCP相关的AE,我们改变了ERCP方法,即在注射造影剂前进行胆汁抽吸,仅采用球囊扩张治疗主要狭窄。对2012年至2014年期间因PSC接受ERCP的所有患者进行了前瞻性测试(第二组)。
与第一组相比,第二组总体AE和胆管炎的风险相对较低[(2.1%对10.3%;P = 0.38)和(0%对4.4%;P = 0.68)]。在双变量分析中,ERCP方法的改变与术后胆管炎风险降低(0%对10.2%,P = 0.03)和总体AE(0%对18.6%,P = 0.03)相关。第二组46例患者中有22例在进行胆汁抽吸和球囊扩张时未发生AE。在多变量分析中,仅胆管支架置入分别与AE风险增加(OR 4.10(1.32至12.71);P = 0.02)和胆管炎风险增加(OR 5.43,1.38至21.38;P = 0.02)相关。
PSC患者在ERCP期间对狭窄进行扩张后进行胆汁抽吸并避免支架置入方法似乎与胆管炎和总体AE风险降低相关。需要未来的前瞻性随机对照试验来验证我们的观察结果。